Roche (headquartered in Basel, Switzerland) and its US subsidiary Genentech (South San Francisco, CA) have built a significant neuroscience portfolio with focus on neurodegeneration, including Alzheimer's disease and Parkinson's disease. Within the ceramide/sphingolipid pathway space, Roche is developing glucocerebrosidase (GCase) modulators — a complementary approach to GCS inhibitors for targeting the [glucosylceramide](/mechanisms/lysosomal-dysfunction-neurodegeneration) pathway in GBA-associated PD and broader neurodegeneration.
Roche's strategy centers on the strong genetic and biological link between GBA mutations and PD risk, developing both GCase chaperones (to enhance residual enzyme activity) and small molecule activators (to boost wild-type GCase function) for potential disease modification.
Glucocerebrosidase (GCase) Biology
Enzyme Function
Glucocerebrosidase (GBA1) is a lysosomal hydrolase that cleaves glucosylceramide into ceramide and glucose:
Glucosylceramide + H2O → Ceramide + Glucose ↑ GCase (GBA1) — deficient in Gaucher disease, reduced in GBA-PD
GBA-PD Connection
Heterozygous GBA mutations are the strongest genetic risk factor for PD
GBA mutations found in 5-15% of PD patients across all ethnicities
GBA-PD patients have earlier onset, more severe cognitive impairment[@af Rosenberger2019]
Therapeutic Strategies
GCase chaperones: Small molecules that bind and stabilize misfolded GCase, enhancing trafficking to lysosomes
GCase activators: Direct allosteric activators of wild-type and variant GCase[@pavan2019]
Substrate reduction: GCS inhibitors (see Sanofi/Ipsen pages)
Gene therapy: AAV-GBA1 delivery
Key Pipeline Agents
1. GCase Chaperone Program (AT337)
Roche's lead GCase chaperone is in early clinical development:
Mechanism: Binds to active site of GCase, promoting proper folding and lysosomal trafficking. Increases enzyme activity by 1.5-3x in patient-derived cells.
Development Status:
Phase 1 completed in healthy volunteers
Phase 1b planned in GBA-PD patients
Preclinical Profile:
Increased GCase activity in iPSC-derived neurons from GBA-PD patients
Reduced glucosylceramide and α-synuclein oligomers
Neuroprotective in GBA-mutant mouse models
Good CNS penetration in non-human primates
2. Small Molecule GCase Activators
AT210 (Structural Analog):
Allosteric GCase activator
Mechanism: binds to a distinct site on GCase, increasing catalytic efficiency
In preclinical development for sporadic PD (no GBA mutation required)
3. Roche/Chugai Collaboration
Roche's partnership with Chugai (Japan) provides access to:
Chugai's antibody engineering platform
Collaborative GCase-targeted programs
Asian population clinical trials for GBA-PD
Clinical Development Summary
Biomarker Strategy
Roche has pioneered biomarker development for GCase-targeted therapies:
Target Engagement Biomarkers
CSF GCase activity (enzyme activity assay)
CSF glucosylceramide (LC-MS/MS)
Disease Progression Biomarkers
CSF α-synuclein (seed amplification assay, SAA)
Neurofilament light chain (NfL)
PET tau/amyloid for AD cohorts
Combination Approaches
Roche is exploring combinations within the sphingolipid pathway:
Cross-References
Related Mechanisms
[Lysosomal Dysfunction in Neurodegeneration](/mechanisms/lysosomal-dysfunction-neurodegeneration)
[Ceramide Signaling Pathway in Neurodegeneration](/mechanisms/ceramide-signaling-neurodegeneration)
Related Therapeutic Pages
[Ceramide and Sphingolipid Modulation Therapy](/therapeutics/ceramide-sphingolipid-modulation-therapy)
[Ambroxol in Parkinson's Disease](/therapeutics/ambroxol-parkinsons)